News Article | May 8, 2017
— Summary Sarcopenia is defined as the loss of mass and muscular function with age. Symptoms include obesity, difficulty walking or moving about, lack of strength and respiratory problems. Treatment includes medications and hormone replacement therapy. Report Highlights This report provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Table of Content: Key Points List of Tables List of Figures Introduction Sarcopenia - Overview Sarcopenia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Sarcopenia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Sarcopenia - Companies Involved in Therapeutics Development Amgen Inc Biophytis SAS GlaxoSmithKline Plc MYOS RENS Technology Inc Neurotune AG Novartis AG PsiOxus Therapeutics Ltd Regeneron Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd Sarcopenia - Drug Profiles ARM-210 - Drug Profile Product Description Mechanism Of Action R&D Progress ATA-842 - Drug Profile Product Description Mechanism Of Action …Continued For more information, please visit http://www.wiseguyreports.com
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: REGIONS | Award Amount: 2.41M | Year: 2010
Challenge: Health-TIES addresses Europes largest health challenges: an ageing population and the sustainability of the healthcare system. This cross-border challenge needs a collaborative approach! Third revolution: True collaboration between medical scientists, engineers, healthcare providers, industry and government is the key to innovation in healthcare (the third revolution). Health-TIES is at the forefront: a transnational consortium in medical technology comprising four top regions in biosciences, technology and entrepreneurship: Biocat (Catalonia), Medical Delta (West Netherlands), Oxford/Thames Valley, Canton de Zurich and a mentoring region szak-Alfld (Hungary). Common goals: To maximise the impact of innovation and RTD on healthcare, Health-TIES will stimulate joint science, education and state-of-the-art infrastructure; and boost the Healthcare Technology Innovation Cycle. S&T meet patients: Breakthroughs in molecular technology, imaging, and drug design have created new avenues for prevention (risk factor identification, early diagnosis) and more effective treatment. Health-TIES will apply these to Cardiovascular diseases, Cancer, Neurodegenerative diseases, Immunology & Infectious diseases. Accelerate innovation: Health-TIES will accelerate the Healthcare Technology Innovation Cycle, which connects engineers and medical professionals, scientists and entrepreneurs, developers and end-users. Policy makers will be engaged in developing the RTD agenda. Analyse, integrate, disseminate: Health-TIES activities include: analysing innovation performance; attracting SMEs; exchanging staff and students; entrepreneurial training; connecting stakeholders; involving end-users in RTD; sharing best-practices through a Virtual Reference Region and ICT-tools. Better health(care): Health-TIES will contribute to improved health of EU citizens, better-equipped medical doctors, more efficient and effective healthcare systems, and an economically viable sector.
Neurotune AG | Date: 2011-03-16
Modified agrin fragment having in vivo activity, comprising at least the domains LG2 and LG3 of human agrin in covalently interlinked form and modified in such a way that the fragment cannot be cleaved by neurotrypsin for use as medicament.
Neurotune AG | Date: 2012-08-08
A method for the production of a hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human C44-fragment of agrin, comprising administering to wild-type-mice an immunizing amount of C44y4-fragment of agrin, isolating antibody producing cells from the immunized mice, fusing them with a myeloma cell line, growing the fused cells in a selection medium, screening the antibodies in the supernatants of hybridoma cells for binding to C44-fragment of agrin and isolating the hybridoma cells producing the desired monoclonal antibodies
Neurotune AG | Date: 2013-07-31
The use of dimiracetam in the treatment of chronic pain chronic pain induced by osteoarthritis, rheumatoid arthritis or autoimmune osteoarthrosis forms is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.
Neurotune Ag | Date: 2013-02-22
Method for the determination of the renal function wherein the amount of at least one agrin fragment derived by neurotrypsin cleavage of agrin is measured in a sample taken from a patient and the measured amount of the agrin-fragment in the sample is used as indicator for renal function.
Neurotune AG | Date: 2016-08-03
Modified agrin fragment having in vivo activity, comprising at least the domains LG2 and LG3 of human or mouse agrin in covalently interlinked form and modified in such a way that the fragment cannot be cleaved by neurotrypsin for use in the treatment of neuromuscular diseases or diseases of nerve, muscle and neuromuscular junctions, wherein the modified agrin fragment is characterized in that its -cleavage site is deleted or modified.
Neurotune Ag | Date: 2011-10-25
Dimiracetam is a suitable drug for treating and preventing allodynia, in particular allodynia of the hands and feet, that is or may be induced by antitumoral chemotherapeutic treatment with sorafenib.
Neurotune AG | Date: 2015-04-08
The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose.
Neurotune AG | Date: 2013-08-28
Immunoassay for the detection of CAF (22-Kd fragment of agrin) in a sample, which additionally can include larger agrin-fragments (110-Kd fragment) and agrin itself and in which the CAF to be detected can be present in one or both of the following 2 different conformations CAF-closed and CAF-open, wherein in an optional first step the larger fragments and agrin possibly present in the sample are removed therefrom, in a second step the remaining portion of the sample obtained after possible removal of the larger fragments in the first step is incubated with a (primary) antibody with known binding properties to the different conformations of the CAF, with the antibody being capable to specifically bind to at least the CAF-open conformation, and in a third step it is determined whether or not antibody-CAF-complexes have been formed after incubation.